Investigations into deviations, reports, and/or follow-up actions were inadequate.
Inspection Record
IMCD Canada Limited — Health Canada Inspection Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
The maintenance of evidence was inadequate for manufacturing, packaging, labelling, required testing, storage, and/or distribution, including the respective conditions.
The availability, content and/or maintenance of the quality agreements between the supplier, fabricator, tester, packager, labeller, distributor, importer, and/or wholesaler was inadequate.
The design of the drug stability study was inadequate and/or not justified with a documented rationale.
The change control system was inadequate for ensuring changes are properly documented, evaluated, and/or approved.
The confirmatory tests conducted on samples before or after they were received in Canada were inadequate.
The assessment to release finished products was inadequate.
The guidelines and/or procedures were inadequate in ensuring storage and/or transportation conditions would maintain the quality and safe distribution of the drug.
The traceability, legibility, documentation, formatting, and/or the accuracy of records was inadequate.
The written procedures for recalls were inadequate.
About this record
Extracted automatically from the document of the Health Canada inspection on 2026-02-19. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
